New class of anti-cancer drugs can combine with chemotherapy to prevent tumors' protective mechanism
Many patients who have been diagnosed with breast cancer are often advised to buy Tamoxifen to reduce the progression of the disease.
Many patients who have been diagnosed with breast cancer are often advised to buy Tamoxifen to reduce the progression of the disease. According to researchers from the Walter and Eliza Hall Institute, some of the more aggressive types of the disease are more susceptible to chemotherapy when patients receive an anti-cancer agent called ABT-737.
This drug targets and neutralizes proteins known as Bcl-2, which have a protective effect on tumor cells that have been subjected to drugs.
Lead author Geoff Lindeman and his colleagues from the institute's Stem Cells and Cancer division published their paper in the journal Proceedings of the National Academy of Sciences, reporting that ABT-737 have great promise in the treatment of triple negative breast cancer.
"ABT-737 targets proteins from the Bcl-2 family, which are found at high levels in up to 70 percent of breast cancers," Lindeman explained. "We have shown that breast tumors that have high levels of Bcl-2 respond well to treatment with ABT-737 when used in combination with a conventional chemotherapy drug."
|
